tradipitant (Nereus)
Jump to navigation
Jump to search
Indications
- prevention of motion sickness
- may prevent gastroparesis, nausea & vomiting with GLP-1 receptor agonists[2]
Dosage
- 85 or 170 mg oral single dose ~60 minutes prior to potential motion sickness event.
Adverse effects
Drug interactions
- driving or operating heavy machinery may be impaired, especially when combined with CNS depressants or strong CYP3A4 inhibitors
Mechanism of action
- oral neurokinin-1 receptor antagonist
- blocks release of substance P
More general terms
References
- ↑ George J FDA Greenlights First Motion Sickness Drug in More Than 40 Years. NK-1 receptor antagonist tradipitant approved to prevent vomiting induced by motion. MedPage Today. December 31, 2025 https://www.medpagetoday.com/neurology/generalneurology/119230
- ↑ 2.0 2.1 Vanda Pharmaceuticals Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting. Vanda Pharmaceuticals Inc. Nov 17, 2025 https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-positive-results-for-tradipitant-in-preventing-glp-1-induced-nausea-and-vomiting-302617739.html